PCN103 - PREDICTED TREATMENT COSTS AND SAVINGS PER PATIENT OF KANJINTI® (TRASTUZUMAB BIOSIMILAR) VS. SUBCUTANEOUS (SC) AND INTRAVENOUS (IV) HERCEPTIN® AND OTHER TRASTUZUMAB BIOSIMILARS IN ITALY
Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.186
https://www.valueinhealthjournal.com/article/S1098-3015(18)33486-7/fulltext
Title :
PCN103 - PREDICTED TREATMENT COSTS AND SAVINGS PER PATIENT OF KANJINTI® (TRASTUZUMAB BIOSIMILAR) VS. SUBCUTANEOUS (SC) AND INTRAVENOUS (IV) HERCEPTIN® AND OTHER TRASTUZUMAB BIOSIMILARS IN ITALY
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)33486-7&doi=10.1016/j.jval.2018.09.186
First page :
Section Title :
Open access? :
No
Section Order :
1210